// App-Quantinova.ai

4575 : Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling.

Researchers

Presenter

  • Matt D. Galsky

Principal Investigators

  • Heidi Wirtz

  • Brian Bloudek

  • Zsolt Hepp

  • Jack Timmons

  • Enrique Lenero

  • Thomas Powles

Medical Centers

  • Tisch Cancer Institute at Mount Sinai, New York, NY

  • Seagen, Inc., Bothell, WA

  • Curta Inc., Seattle, WA

  • Seagen, Inc., Bothell, WA

  • Astellas Pharma Global Development, Inc., Northbrook, IL

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • Astellas Pharma US,

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

Drug/Treatment

  • 1L platinum

  • Avelumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved